ASXL1 prognosis in intermediate-risk cytogenetic AML and NPM1 mutations: For assessing the impacts of intermediate-risk cytogenetics and NPM1 mutations on the prognosis of ASXL1 mutations, we initially selected studies evaluating OS in AML patients with an intermediate-risk cytogenetic profile. The gene discussed is ASXL1; the disease is acute myeloid leukemia.